In the slow lane: why the UK must rethink its barriers to novel medicines



The early access to medicines scheme has been running for six years, but has it had the desired impact of ensuring the sickest patients are spared the wait for the most promising treatments, or is it failing to live up to expectations?


Source link

Share and Enjoy !

0 0